Analyst Price Target on Prima BioMed Ltd (NASDAQ:PBMD) December...

Analyst Price Target on Prima BioMed Ltd (NASDAQBMD)

December 11, 2015
Prima BioMed Ltd (NASDAQBMD): The stock price is expected to reach $ 4.5 in the short term. The number of analysts agreeing with this consensus is 2. The higher estimate for the short term price target is at $6 while the lower estimate is at $3. The standard deviation of the price stands at $2.12.
During the last several months other analysts have commented on the company rating. FBR Capital initiates coverage on Prima BioMed Ltd (NASDAQBMD). The shares have now been rated Outperform by the stock experts at the ratings house. FBR Capital announces the current price target of $6 per share on Prima BioMed Ltd. The rating by the firm was issued on December 3, 2015.
As many as 2 brokerage firms have rated Prima BioMed Ltd (NASDAQBMD) at 2. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. The stock garnered a place in the hold list of 1 stock Analysts. 1 analysts rated the company as a strong buy.
Prima BioMed Ltd (NASDAQBMD) : On Thursday heightened volatility was witnessed in Prima BioMed Ltd (NASDAQBMD) which led to swings in the share price. The shares opened for trading at $1.14 and hit $1.2201 on the upside , eventually ending the session at $1.2, with a gain of 4.35% or 0.05 points. The heightened volatility saw the trading volume jump to 795,030 shares. The 52-week high of the share price is $6.48 and the company has a market cap of $70 million. The 52-week low of the share price is at $0.4211 .
Institutional Investors own 1.2% of Prima BioMed Ltd shares.